Nexell Therapeutics Inc.

The Irvine supplier of therapeutic and diagnostic products posted a second-quarter net loss of $10 million, or 14 cents a share, compared with a net loss of $10.3 million, or 15 cents a share, for the same period last year. Revenue dropped 52% to $1.6 million. The company attributed the sales decline to the repurchase of inventory from Baxter Healthcare Corp.